Adverse events and inefficacy of PCSK9 Inhibition with evolocumab or alirocumab in hypercholesTeraemic pAtients. (AKITA) First published 24/02/2020 Last updated 24/02/2020 EU PAS number:EUPAS33787 Study Planned